CAR-T 细胞疗法治疗胶质母细胞瘤的安全性和疗效：一项系统性综述和荟萃分析

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis.

尽管 CAR-T 细胞疗法在胶质母细胞瘤患者中是一种相对安全的治疗选择，但其疗效有限，提示有必要进一步研究以将其转化为复发性胶质母细胞瘤治疗的临床实践。

优化基于 CAR-T 细胞的治疗策略以增强胶质母细胞瘤治疗抗肿瘤疗效的研究进展

Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment.

放疗预处理增强 B7-H3-CAR-T 治疗实体瘤模型的疗效

Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.

我们的结果提示，B7-H3-CAR-T 疗法联合放疗可能是治疗实体瘤的一种有前景的方式。

双特异性 c-Met/PD-1 CAR-T 细胞对实体瘤具有增强的治疗效果

Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.

表达 IL7/CCL19 的 CAR-T 细胞在胶质母细胞瘤和胰腺癌难治性实体瘤模型中的治疗疗效

Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.

面向实体瘤的工程化 CAR-T 细胞：通过整合设计与临床转化克服微环境

Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation.

肉瘤及其他实体瘤中的细胞治疗

Cellular therapies in sarcoma and other solid tumors.

NK 细胞疫苗在实体瘤临床试验中的优势：多种生物学策略与技术的实施

The advantages of NK cell vaccines in solid carcinoma clinical trials: conducted by various biology strategy and technology.

IL13Rα2 靶向 CAR-T 细胞治疗复发恶性胶质瘤的 I 期试验：临床结果与药代动力学

Phase I trial of IL13Rα2-targeted CAR-T cell therapy for recurrent malignant glioma: clinical results and pharmacokinetics.

静脉注射 IL13R 2 靶向 CAR-T 疗法耐受性良好，并显示出初步安全性。需要进一步研究以优化给药方案和预处理方案，并确定用于疗效评估的探索性生物标志物。

NLGN4X TCR 转基因 T 细胞治疗胶质瘤

NLGN4X TCR transgenic T cells to treat gliomas.

NLGN4X-TCR-T 在临床前胶质母细胞瘤模型中显示出疗效。